Pharmaceutical

IGC Pharma heads towards a Phase I study for Alzheimer’s disease

With TGR-63 advancing towards the clinical stage, IGC Pharma is tackling different small molecule alternatives to treat Alzheimer’s.

Feb 2, 2024 - 18:00
IGC Pharma heads towards a Phase I study for Alzheimer’s disease
With TGR-63 advancing towards the clinical stage, IGC Pharma is tackling different small molecule alternatives to treat Alzheimer’s.
Read the original article

Tags:

Previous Article

BMS reports 2% revenue loss in 2023 after Revlimid generics hurt sales

Next Article

AbbVie wins UK NICE endorsement for subcutaneous Tepkinly in DLBCL

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Tavros and OpenBench expand small molecule drug discovery alliance

Tavros and OpenBench expand small molecule drug discove...

Apr 28, 2023

An artist uses the canvas to make sense of her partner’s illness, and her own

An artist uses the canvas to make sense of her partner’...

May 9, 2023

Discrimination lawsuit against HHMI spotlights barriers faced by scientists with disabilities

Discrimination lawsuit against HHMI spotlights barriers...

Apr 19, 2023